admin

Better therapy for patients with heart failure and atrial fibrillation (CABA-HFPEF-DZHK27 trial)

by

The study “CABA-HFPEF-DZHK27” (CAtheter-Based Ablation of atrial fibrillation vs. conventional treatment in patients with Heart Failure with Preserved Ejection Fraction) is aiming for a better therapy for patients with heart failure and atrial fibrillation. Charité (Berlin, Germany) has the overall responsibility for the study. This trial is supported by German Centre for Cardiovascular Research (DZHK). Further information can be found in the press release (german only). 

Attaining sinus rhythm mediates improved outcomes with early rhythm control therapy of atrial fibrillation

by

A mediator analysis of the EAST – AFNET 4 trial dataset revealed the key factor for the effectiveness of early rhythm control (ERC) in patients with atrial fibrillation (AF): The presence of sinus rhythm at 12 months after randomization explains 81% of the outcome-reducing effect of ERC. Other factors, e. g. blood pressure or recurrent AF, only explain small portions of the effect. The results were presented by Professor Lars Eckardt, University Hospital Münster, Germany, at the annual congress of the European Society of Cardiology (ESC) in Barcelona, Spain, on 29.08.2022 [1], [2].

8th AFNET/EHRA Consensus Conference 2021 Paper published

by

Posts NEWS Mon, 08.08.2022 8th AFNET/EHRA Consensus Conference 2021 Paper published The 8th AFNET/EHRA Consensus Conference Paper 2021 “Early diagnosis and better rhythm management to improve outcomes in patients with atrial fibrillation” has been published: https://academic.oup.com/europace/advance-article/doi/10.1093/europace/euac062/6650662  

EAST-AFNET 4 @ ESC 2022

by

Posts NEWS Thu, 07.07.2022 EAST-AFNET 4 @ ESC 2022 The newest subanalysis of the EAST-AFNET 4 study will be presented at this year’s ESC congress 2022 in Barcelona: Latest science in atrial fibrillationPredictors and mediators of improved outcomes on early rhythm control an analysis of the EAST AFNET – 4 data set.Monday, 29th of August … Read more

Subanalysis of the EAST – AFNET 4 trial: Patients with AF and high comorbidity burden benefit from early rhythm control

by

Posts NEWS Fri, 29.04.2022 Subanalysis of the EAST – AFNET 4 trial: Patients with AF and high comorbidity burden benefit from early rhythm control Press release Subanalysis of the EAST – AFNET 4 trial: Patients with AF and high comorbidity burden benefit from early rhythm control Early rhythm control therapy reduces cardiovascular complications compared to … Read more

EAST-AFNET 4 @ EHRA 2022

by

The latest results of the EAST-AFNET 4 study will be presented at this year’s EHRA congress 2022:

Late Breaking Clinical Trials II
Atrial fibrillation – News on ablation and sex differences
Monday, 4th of April 2022 | 6:15 pm – 7:15 pm (CEST), Room 1
Session chaired by Tatjana Potpara
More information

EAST – AFNET 4 trial: Patients with first diagnosed atrial fibrillation (AF) benefit from early rhythm control

by

Early rhythm control is useful in patients with atrial fibrillation regardless of the AF pattern. Patients with first diagnosed atrial fibrillation benefit from early rhythm control therapy comparably to patients with paroxysmal or persistent AF. This is the result of a subgroup analysis of the EAST – AFNET 4 trial that was presented by Professor Andreas Goette, St. Vincenz Hospital Paderborn, at the American Heart Association (AHA) congress on 14.11.2021 in Boston [1].

Early rhythm control improves outcomes in patients with asymptomatic atrial fibrillation

by

Asymptomatic patients with atrial fibrillation (AF) benefit from early rhythm control therapy comparably to symptomatic patients. This is the result of a subgroup analysis of the EAST – AFNET 4 trial that was presented by Professor Stephan Willems, Asklepios Hospital St. Georg, Hamburg, at the annual congress of the European Society of Cardiology (ESC) on 27.08.2021 [1] and published in the European Heart Journal [2].